Skip to main content
main-content

12-09-2022 | ESMO 2022 | Conference coverage | Video

IMvigor130 analysis highlights need to standardize PD-L1 expression assessment

share
SHARE

Enrique Grande Pulido takes us through an exploratory analysis of the IMvigor130 trial of atezolizumab in metastatic urothelial cancer focusing on the differences in outcomes according to the assay used to assess PD-L1 expression, and highlights the clinical relevance of the findings (5:14).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.